# US 2023/0404959 A1 · Topical formulation comprising omega-3 fatty acids, melatonin and vitamin d

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404959 A1
- Document ID: US20230404959A1
- Status: Published application
- Kind: A1
- Application number: 18/035,690
- Filed: 2021-11-04
- Published: 2023-12-21
- Earliest claimed: 2020-11-05
- Assignees: Ambo Innovations, LLC
- Applicants: Ambo Innovations LLC
- Inventors: Bo Martinsen
- Web page: https://patentgrep.com/patent/US20230404959A1

## CPC

- A61K 9/0043: {Nose}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61P 17/00: Drugs for dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides topical formulations comprising omega-3 fatty acids, melatonin, vitamin D3 and optionally β-glucan. The formulations are designed for application to either the skin or mucosa of a subject in need thereof. The present disclosure also provides methods of treatment or prevention of a variety of conditions by applying the formulations to the skin or mucosa of the subject, including various skin conditions, eye disorders and sleep disorders.

## Claims

### Claim 1

A topical formulation comprising:
an omega-3 fatty acid component comprising eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA), or a combination thereof;
melatonin;
vitamin D3; and
at least one topical carrier.

### Claim 2 (depends on 1)

The topical formulation of claim 1, wherein the omega-3 fatty acid comprises EPA and DPA.

### Claim 3 (depends on 2)

The topical formulation of claim 2, wherein the EPA and DHA have a EPA:DHA weight ratio ranging from about 0.5:1.5 to about 1.5:0.5.

### Claim 4 (depends on 3)

The topical formulation of claim 3, wherein the EPA:DHA weight ratio ranges from about to about 1.25:0.75; about 0.8:1.2 to about 1.2:0.8; or about 0.9:1.1 to about 1.1:0.9.

### Claim 5 (depends on 3)

The topical formulation of claim 3, wherein the EPA:DHA weight ratio is about 1:1.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The topical formulation of any one of claims 1 to 5, wherein the omega-3 fatty acid consists essentially of the EPA and the DHA.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The topical formulation of any one of claims 1 to 6, wherein the omega-3 fatty source is a purified fish oil.

### Claim 8 (depends on 7)

The topical formulation of claim 7, wherein the purified fish oil is a purified fish liver oil.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The topical formulation of any one of claims 1 to 8, wherein the topical formulation comprises:
about 2 to about 25% by weight of the omega-3 fatty acid component,
about 0.1 to about 15% by weight of the melatonin, and about
about 0.005 to about 1% by weight of the vitamin D3.

### Claim 10 (depends on 9)

The topical formulation of claim 9, wherein the topical formulation comprises:
about 5 to about 15% by weight of the omega-3 fatty acid component,
about 0.1 to about 1% by weight of the melatonin, and about
about 0.01 to about 0.1% by weight of the vitamin D3.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The topical formulation of any one of claims 1 to 10, further comprising a plant-derived β-glucan.

### Claim 12 (depends on 11)

The topical formulation of claim 11, wherein the β-glucan is an oat or barley (cereal) fiber β-glucan.

### Claim 13 (depends on 11, 12)

The topical formulation of claim 11 or 12, wherein the topical formulation comprises about 1 to about 10% by weight of the β-glucan.

### Claim 14 (depends on 13)

The topical formulation of claim 13, wherein the topical formulation comprises about 1 to about 5% by weight of the β-glucan.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The topical formulation of any one of claims 1 to 14, further comprising eucalyptus oil.

### Claim 16 (depends on 15)

The topical formulation of claim 15, wherein the topical formulation comprises about 0.1 to about 5% by weight of the eucalyptus oil.

### Claim 17 (depends on 16)

The topical formulation of claim 16, wherein the topical formulation comprises about 0.1 to about 1% by weight of the eucalyptus oil.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The topical formulation of any one of claims 1 to 17, further comprising at least one cannabinoid.

### Claim 19 (depends on 18)

The topical formulation of claim 18, wherein the cannabinoid is chosen from cannabidiol (CBD), cannabidiolic acid (CBDA), cannabinol (CBN), Cannabinolic acid (CBNA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabichromene (CBC), cannabichromenic acid (CBCA), cannabicyclol (CBL), cannabicyclolic acid (CBLA), cannabivarin (CBV), cannabivarinic acid (CBVA), tetrahydrocannabivarin (THCV), tetrahydrocannabivarinic acid (THCVA) cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabichromevarin (CBCV), cannabichromevarinic acid (CBCVA), cannabigerovarin (CBGV), cannabigerovarinic acid (CBGVA), and any combination thereof.

### Claim 20 (depends on 18, 19)

The topical formulation of claim 18 or 19, wherein the topical formulation comprises about to about 15% by weight of the at least one cannabinoid.

### Claim 21 (depends on 20)

The topical formulation of claim 20 wherein the topical formulation comprises about 0.1 to about 10%, about 0.1 to about 5%, about 0.1% to about 1% by weight of the at least one cannabinoid.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The topical formulation of any one of claims 1 to 21, further comprising ferulic acid.

### Claim 23 (depends on 22)

The topical formulation of claim 22, wherein the topical formulation comprises about 0.1 to about 5% by weight of the ferulic acid.

### Claim 24 (depends on 23)

The topical formulation of claim 23, wherein the topical formulation comprises about 0.1 to about 1% by weight of the ferulic acid.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The topical formulation of any one of claims 1 to 24, further comprising a vitamin chosen from vitamin A, vitamin B3, vitamin E, and combinations thereof.

### Claim 26 (depends on 25)

The topical formulation of claim 25, wherein the formulation comprises the vitamin B3.

### Claim 27 (depends on 26)

The topical formulation of claim 26, wherein the topical formulation comprises about 0.1 to about 5% of the vitamin B3.

### Claim 28 (depends on 26)

The topical formulation of claim 26, wherein the topical formulation comprises about 0.1 to about 1% of the vitamin B3.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The topical formulation of any one of claims 1 to 28, further comprising a source of a medium chain fatty acid.

### Claim 30 (depends on 29)

The topical formulation of claim 29, wherein the source of the medium chain fatty acid comprises coconut oil.

### Claim 31 (depends on 30)

The topical formulation of claim 30, wherein the topical formulation comprises about 1 to about 10% by weight of the coconut oil.

### Claim 32 (depends on 31)

The topical formulation of claim 31, wherein the topical formulation comprises about 1 to about 5% by weight of the coconut oil.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The topical formulation of any one of claims 1 to 32, wherein the formulation is formulated as a gel, lotion, solution, cream, ointment, oil, dressing, foam, spray, or film.

### Claim 34 (depends on 33)

The topical formulation of claim 33, wherein the topical formulation is formulated as a cream, ointment, or lotion.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The topical formulation of any one of claims 1 to 34, wherein the topical carrier further comprises water, hyaluronic acid, lecithin, and/or glycerin.

### Claim 36 (depends on 35)

The topical formulation of claim 35, wherein the topical formulation comprises about 50 to about 80% by weight of the water.

### Claim 37 (depends on 36)

The topical formulation of claim 36, wherein the topical formulation comprises about 60 to about 75% by weight of the water.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The topical formulation of any one of claims 1 to 37, wherein topical carrier comprises about to about % by weight of the hyaluronic acid.

### Claim 39 (depends on 38)

The topical formulation of claim 38, wherein the topical formulation comprises about by weight of the hyaluronic acid.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The topical formulation of any one of claims 1 to 39, wherein the topical formulation is formulated for application to skin.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The topical formulation of any one of claims 1 to 39, wherein the formulation is formulated for application to mucosa.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The topical formulation of any one of claims 1 to 39, wherein the formulation is formulated for application to the eye lids.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The topical formulation of any one of claims 1 to 42, wherein the topical formulation further comprises at least one additional biologically active agent.

### Claim 44 (depends on 43)

The topical formulation of claim 43, wherein the at least one biologically active agent is chosen from an antibiotic, an anti-inflammatory, an anti-cancer, an enzyme inhibitor, a TRP modulator, a topical steroid, or an analgesic.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for treating or preventing dysbiosis and/or strengthening surface barriers of the skin or mucosa of a subject in need thereof comprising applying to the skin or mucosa an effective amount of a topical formulation according to any one of claims 1 to 44.

### Claim 46 (depends on 45)

The method of claim 45, wherein the dysbiosis and/or surface barrier is on the skin.

### Claim 47 (depends on 45)

The method of claim 45 wherein the dysbiosis and/or surface barrier is on the mucosa.

### Claim 48 (depends on 47)

The method of claim 47, wherein the mucosa is nasal, oral, ocular, genital, anal, or rectal.

### Claim 49 (depends on 48)

The method of claim 48, wherein the mucosa is the nasal mucosa or oral mucosa.

### Claim 50 (depends on 49)

The method of claim 49, wherein the mucosa is nasal mucosa.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for promoting sleep or treating a sleep disorder in a subject in need thereof comprising applying the topical formulation of any one of claims 1 to 44 to the eye lids or nasal mucosa of the subject.

### Claim 52 (depends on 51)

The method of claim 51, wherein the sleep disorder is sleep apnea, jet lag, or insomnia.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for treating or preventing a mucosal site condition in a subject in need thereof comprising applying an effective amount the topical formulation according to any one of claims 1 to 44 to the mucosa of the subject.

### Claim 54 (depends on 53)

The method of claim 53, wherein the mucosa is nasal, oral, ocular, genital, anal, or rectal mucosa.

### Claim 55 (depends on 54)

The method of claim 54, wherein the mucosa is nasal mucosa.

### Claim 56 (depends on 55)

The method of claim 55, wherein the mucosal site condition is pollen allergy, chronic rhinosinusitis, nasal dysbiosis, asthma, viral infection, bacterial infection, or any combination thereof.

### Claim 57 (depends on 55, 56)

The method of any one of claim 55 or 56, wherein the method comprises applying the formulation by nasal spray, swab, or squeeze tube.

### Claim 58 (depends on 53)

The method of claim 53 wherein the mucosa is the oral mucosa.

### Claim 59 (depends on 58)

The method of claim 58, wherein the mucosal site condition is mucosal dryness, gingivitis, periodontitis, oral lichen planus, herpes labialis, candidiasis, ulcer, or any combination thereof.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for treating or preventing a dermatological condition in a subject in need thereof comprising applying an effective amount of the formulation according to any one of claims 1 to 44 to the skin of the subject.

### Claim 61 (depends on 60)

The method according to claim 60, wherein the dermatological condition comprises eczema, pruritus, psoriasis, rash, hives, contact dermatitis, insect bite, allergic reaction, rosacea, acne, cold sores, blisters, hives, actinic keratosis, fungal infections, insect stings, burns, frost-bite, sun burn, UV radiation protection, post-surgical cuts, stomal site irritation, radiation therapy skin burns, photo-aging, abrasions, basal cell carcinoma, squamous cell carcinoma, melanoma, bed sores, parasitic infection, spider bites, shingles, infected wounds, seborrheic dermatitis, contact dermatitis, or any combination thereof.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method for preventing or reducing dry eye, ocular tension, glaucoma, or retinal conditions in a subject in need thereof comprising applying a formulation of any one of claims 1 to 44 to the eye or eye lids of a subject in need thereof.

### Claim 63 (depends on 62)

The method of claim 62, further comprising applying the formulation to the nasal mucosa.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of treating vaginal dryness, vaginal or vulvar atrophy, or hot flashes comprising applying to the skin or mucosa an effective amount of a topical formulation according to any one of claims 1 to 44 to the vaginal mucosa of a subject in need thereof.

### Claim 65 (depends on 64)

The method of claim 64, wherein the disorder or condition is vaginal dryness, vaginal or vulvar atrophy.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A perioperative treatment method for cataract or lasik surgery comprising applying a formulation of any one of claims 1 to 44 to the eye or eye lids of a subject in need thereof.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of preventing or reducing ear ache in a subject in need thereof comprising applying the formulation of any one of claims 1 to 44 to the ear canal of a subject in need thereof.

### Claim 68 (depends on 43, 44)

A method of topically delivering a biologically active agent comprising applying an effective amount of a composition according to claim 43 or 44 to the skin or mucosa of a subject in need thereof.

### Claim 69 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 45 to 68, wherein the effective amount of the topical formulation is about 50 mg to about 200 mg.
